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The endothelium is required for maintenance of vas-
cular integrity and homeostasis during vascular devel-
opment and in adulthood. However, little is known
about the coordinated interplay between transcription
factors and signaling molecules that regulate endothe-
lial cell-dependent transcriptional events. Vascular en-
dothelial zinc finger-1 (Vezf1) is a zinc finger-containing
transcription factor that is specifically expressed within
the endothelium during vascular development. We
have previously shown that Vezf1 potently activates
transcription of the endothelin-1 promoter. We now
report the identification of p68RacGAP, a novel Vezf1-
interacting 68-kDa RhoGAP domain-containing pro-
tein. p68RacGAP mRNA is highly expressed in vascu-
lar endothelial cells by Northern blot analysis, and
immunohistochemical staining of adult mouse tissues
identified p68RacGAP in endothelial cells, vascular
smooth muscle cells, and epithelial cells in vivo. Rac1
and Vezf1 both bind avidly to p68RacGAP, suggesting
that p68RacGAP is not only a GTPase-activating pro-
tein for Rac1 but that p68RacGAP may also be part of
the protein complex that binds to and modulates Vezf1
transcriptional activity. Functionally p68RacGAP spe-
cifically activates the GTPase activity of Rac1 in vivo
but not Cdc42 or RhoA. In addition, p68RacGAP
potently inhibits Vezf1/DB1-mediated transcriptional
activation of the human endothelin-1 promoter and
modulates endothelial cell capillary tube formation.
Taken together, these data suggest that p68RacGAP is
a multifunctional regulatory protein that has a Rac1-
specific GTPase-activating activity, regulates tran-
scriptional activity of the endothelin-1 promoter, and
is involved in the signal transduction pathway that
regulates endothelial cell capillary tube formation
during angiogenesis.
Angiogenesis, the sprouting of new blood vessels from an
existing primary vascular complex, is a highly regulated proc-
ess under normal conditions; it accounts for neovascularization
that occurs during wound healing and during the female repro-
ductive cycle. However, many disease processes are driven by
persistent unregulated angiogenesis. These include diabetic
retinopathies, inflammatory states such as rheumatoid arthri-
tis, and tumor growth and metastasis (1). The sprouting of new
blood vessels during angiogenesis requires cell migration, a
principal feature not only in embryonic development, where
cell migration is required for movement of differentiating stem
cells and for the coordinated movement required for proper
vascular and organ formation, but also in maintenance of tis-
sue integrity after an insult and in immune surveillance.
Cell migration is usually initiated in response to extracellu-
lar cues that stimulate transmembrane receptors to initiate
intracellular signaling. Cell movement requires the dynamic
reorganization of the actin cytoskeleton, a process that is reg-
ulated by Ras homology (Rho)1 proteins. Rho proteins form a
subgroup of the Ras superfamily of 20–30-kDa GTP-binding
proteins that regulate a wide spectrum of cellular activities (2).
To date, 25 mammalian Rho GTPases have been identified with
RhoA, Rac1, and Cdc42 being the most characterized (3). These
proteins act as molecular switches that cycle between an inac-
tive, GDP-bound and an active, GTP-bound form. Among the
regulatory proteins crucial for Rho GTPase function are gua-
nine nucleotide exchange factors, which promote activation of
Rho GTPase through GDP-GTP exchange, and GTPase-acti-
vating proteins (GAPs), which stimulate intrinsic GTPase ac-
tivity and inactivate Rho GTPases (4, 5). The net effect of the
activation and deactivation signal is a tightly regulated trans-
duction mechanism. The RhoGAP family is defined by the
presence of a 150-amino acid homology region, designated the
RhoGAP domain, which is necessary and sufficient for GAP
activity and shares at least 20% sequence identity among fam-
ily members (6). Specific roles for RhoGAP family members in
endothelial cell events have not been clearly defined, although
members of this family are likely to be crucial regulators of
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endothelial migratory events that are required during
angiogenesis.
The GTPase-induced GTP hydrolysis is a key event in intra-
cellular signal transduction that controls numerous vital pro-
cesses, including actin reorganization; gene transcription; ves-
sel trafficking; cell proliferation, survival, and differentiation;
and motility. The coordinated movement of cells depends on
promotion of protrusions (lamellipodia) by Rac1 and formation
of new cell adhesions to adjacent cell matrix at the leading
edge. In addition, Rho-dependent actin-myosin contraction in
the cell body and tail retraction are required to allow the body
and rear of the cell to follow the extending front (7). Thus, the
actin cytoskeleton provides the driving force for cell migration
through its role in promoting both protrusive force toward and
contraction and retraction away from a stimulus in response to
extracellular cues.
Connolly et al. (8) demonstrated that Rac is required for
endothelial cell capillary assembly in vitro. In addition,
WAVE2, a Rac effector protein crucial for Rac-induced mem-
brane ruffling, assists in the formation of lamellipodia at the
leading edge, and WAVE2 knock-out mice die at embryonic day
10 due to impaired angiogenesis that is presumably secondary
to impaired migration of endothelial cells (9). These observa-
tions are also consistent with studies demonstrating that Rac1-
deficient embryos die before embryonic day 9.5 primarily due to
deficient cell migration during and after gastrulation (10).
Taken together, these observations indicate that tight coupling
exists between signaling events and endothelial cell migration
for proper blood vessel growth, creating a need for careful
regulation of Rho and related proteins.
Vascular endothelial zinc finger-1 (Vezf1) was discovered by
Stuhlman and colleagues (11) using a retroviral screen for
developmentally regulated genes. Structurally Vezf1 and its
human homologue, DB1 (12), have six N-terminal Cys2/His2-
type zinc finger motifs as well as a C-terminal proline-rich
region characteristic of a transcriptional activation domain.
Vezf1 mRNA expression is detected from embryonic day 7.25 to
11.5 in mouse embryos, and its expression overlaps with other
endothelial cell-specific markers (11). We have previously
shown that endothelin-1 (a vasoactive peptide that is predom-
inantly expressed in endothelial cells) is one of the downstream
genes that are potently and specifically transactivated by Vezf1
(13). We have also shown that Vezf1 binds to the response
element ACCCCC within the endothelin-1 promoter. Given the
endothelial cell-specific expression of Vezf1, its overlapping
expression with other endothelial cell-specific markers, and our
previous characterization of Vezf1 transcriptional regulation of
endothelin-1, we chose to use Vezf1 as a bait to screen for other
proteins that associate with Vezf1 and regulate blood vessel
formation.
In the process of searching for Vezf1-interacting partners, we
discovered a novel RhoGAP protein, p68RacGAP. p68RacGAP
is expressed predominantly in endothelial cells. It has a Rac1-
specific GTPase activity in vitro and in vivo, and it dose-de-
pendently inhibits Vezf1-dependent transcriptional activation
of endothelin-1 promoter activity. p68RacGAP modulates en-
dothelial cell shape changes and angiogenesis in vivo indicat-
ing that p68RacGAP is a potential link between transcriptional
endothelial cell differentiation programs and cell signaling
pathways required in adult angiogenesis.
MATERIALS AND METHODS
Plasmids—Plasmids pGL2-Basic, pGL2-Promoter, pCMV-Gal,
pGL2–204/170, pME18S-DB1, GST-vector, GST-Vezf1, and GFP-
Vezf1 have already been described (11, 13). Bacterial expression vectors
encoding glutathione S-transferase (GST) fusion proteins of wild type
(GST-RhoA, GST-RhoB, GST-Rac1, and GST-Cdc42) or GTPase-
deficient, GAP-insensitive (GST-RhoAQ63L, GST-Rac1Q61L, and
GST-Cdc42Q61L) human Rho GTPases or the isolated GTP-dependent
binding domain for PAK1 (GST-PBD) or Rhotekin (GST-RBD) or
mammalian expression vectors encoding RhoGAPs (pCMV-p50RhoGAP
and pCMV-p190RhoGAP) have been described elsewhere (14).
Full-length p68RacGAP was subcloned into the EcoRI/SalI site of
pCMV-Tag3B (Stratagene) to generate Myc epitope-tagged Myc-
p68RacGAP; Myc-p68RacGAP-R70A was subsequently generated by
site-directed mutagenesis (see below). Full-length p68RacGAP was sub-
cloned into the NotI/HindIII site of pAdTrack-CMV to generate an
adenovirus that bicistronically expresses p68RacGAP and green fluo-
rescent protein (GFP). pPC86 and pDBleu were obtained from Invitro-
gen. pGADT7 and pGBKT7 were obtained from BD Biosciences.
Cells and Reagents—The culture of myocardial endothelial cells
(MECs), NIH/3T3, COS-7, and C2C12 cells has been described previ-
ously (13). 293 and rabbit endothelial vascular cells were obtained from
the Tissue Culture Facility at Lineberger Comprehensive Cancer at the
University of North Carolina at Chapel Hill. HUVECs were obtained
from Clonetics. Anti-Myc antibody 9E10 and Texas Red-conjugated
phalloidin were obtained from Santa Cruz Biotechnology and Molecular
Probes, respectively. Matrigel was obtained from BD Biosciences.
Yeast Two-hybrid Screening—A yeast two-hybrid screen was per-
formed with the PROQUEST two-hybrid system (Invitrogen). The six
zinc finger domain of Vezf1 was fused with the GAL4 DNA binding
domain in pDBleu and used as a bait. A mouse day 10.5 cDNA embryo
library in pPC86, which expresses fusions with the GAL4 activation
domain, was screened for potential prey in the yeast strain MaV203. A
total of 1  107 independent clones was screened. The screen is depend-
ent on the interaction between the bait and prey to complement His
auxotrophy. Of 25 His/Ura colonies, 11 were also LacZ. pPC86-
based plasmids from these colonies were isolated from yeast and trans-
formed into bacteria. To eliminate false positives, these plasmids were
separately transformed into yeast (MaV203) containing either bait,
several negative control plasmids, or the p53 binding site, and trans-
formants were tested for -galactosidase activity using the colony lift
assay; candidate cDNA inserts were sequenced and used to query
the GenBankTM.
RNA Preparation and Northern Blot Analysis—Total RNA from cells
in culture was prepared by guanidinium isothiocyanate extraction and
centrifugation by calcium chloride methods (15). The quality of the RNA
was analyzed by agarose-formaldehyde gel electrophoresis, and quan-
tification was performed spectrophotometrically. Purified RNA was
separated by agarose-formaldehyde gel electrophoresis and transferred
to a nitrocellulose membrane by capillary action. The membrane was
subsequently subjected to hybridization in the Quickhyb hybridization
buffer (Stratagene) with a [32P]dCTP randomly labeled 1.8-kb cDNA
fragment of p68RacGAP originally isolated from the yeast two-hybrid
screen. An adult multiple organ polyadenylated RNA blot used to ana-
lyze tissue distribution was obtained from OriGene Technologies.
Binding Assays—To test the interactions between p68RacGAP and
Vezf1 or GTPase proteins, binding assays were performed with 30 g of
Vezf1, the indicated GTPase proteins or control proteins as GST fusions
bound to glutathione-Sepharose 4B beads, and 500 g of lysates from
COS-7 cells transfected with vector or Myc-p68RacGAP, Myc-
p50RhoGAP, or Myc-p190RhoGAP. A GST pull-down and anti-Myc blot
were performed as described previously (16).
To determine the GAP activity of p68RacGAP against putative small
GTPase, 30 g of freshly prepared GST-PBD or GST-RBD were incu-
bated with 500 g of COS-7 lysates transiently transfected with plas-
mids expressing Myc-Rac1-WT, Myc-Cdc42-WT, Myc-RhoA-WT, Myc-
p68RacGAP, Myc-p68RacGAP-R70A, Myc-p50RhoGAP, Myc-
p190RhoGAP, Myc-Rac1Q61L, Myc-RhoAQ63L, or Myc-Cdc42Q61L.
Binding assays were performed by lysing the cells containing Rac1 or
Cdc42 in Buffer B (50 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100,
0.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin
and aprotinin) or cells containing RhoA in Buffer A (50 mM Tris, pH 7.6,
500 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100,
0.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml
leupeptin and aprotinin) with rocking for 30 min at 4 °C. Beads were
pelleted at 14,000 rpm for 30 s and washed three times with Buffer B.
The final pellet was resuspended in SDS sample buffer and separated
by 15% SDS-PAGE. Gels were transferred to polyvinylidene difluoride
membrane, and bound proteins were immunoblotted with monoclonal
anti-Rac (1:1000), anti-Cdc42 (1:250), or anti-RhoA (1:250) from Trans-
duction Laboratories.
Immunoprecipitation—To test the interaction between p68RacGAP
and Vezf1 in endothelial cells, cell lysates from non-transfected MECs
were incubated with polyclonal antibody to p68RacGAP as described
previously (16) and blotted with anti-Vezf1 antibody (13).
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FIG. 1. Cloning and analysis of the
p68RacGAP cDNA. A, schematic of
Vezf1 protein showing the zinc finger do-
mains and the proline-rich region. A por-
tion of the protein used for yeast two-
hybrid screen is underlined. B, nucleotide
(upper row) and deduced amino acid
(lower row) sequences. The open reading
frame contains 2,073 bases coding for 571
amino acids with a predicted molecular
weight of 68 kDa. The upstream stop
codon and the RhoGAP domain (single
line) and the partial ERM domain (dotted
lines) are underlined. C, phylogenetic tree
produced by amino acid sequence align-
ment of the RhoGAP homology domain of
p68RacGAP with the catalytic domain of
eight other RhoGAP-containing proteins.
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Mutagenesis—Site-directed mutagenesis of Myc-p68RacGAP was
performed by PCR as described previously (13) to generate the plasmid
Myc-p68RacGAP-R70A that lacks the critical arginine finger. The se-
quence CCTCTTCCGGATGCCT was mutated to CCTCTTCGGGAT-
GCCT with the mismatched primers 5-CAGTGAAGAGGGCCTCTTC-
CGGATGCCTGGCCAGG-3 and 5-CCTGGCCAGGCATCCGGAAGA-
GGCCCTCTTTCAACTG-3. The sequence of the mutated PCR
fragment was confirmed by the dideoxy chain termination method.
Intracellular Localization—To test for co-localization of p68RacGAP
and Vezf1, NIH/3T3 cells (grown in 6-well plates on coverslips) were
transiently transfected with GFP-Vezf1 and pCMV-p68RacGAP using
the LipofectAMINE method (Invitrogen). Twenty-four hours after
transfection, cells were washed three times with 2 ml of phosphate-
buffered saline and permeabilized with blocking buffer (1% bovine
serum albumin, 0.5% Triton X-100 in phosphate-buffered saline) for 10
min. Blocking buffer was washed two times with phosphate-buffered
saline, and cells were incubated in primary antibody (1:1000 anti-Myc
9E10 in blocking buffer) for 2 h. Cells were washed again and subse-
quently incubated for 1 h with 1:400 TRITC-conjugated goat anti-mouse
antibody. Cells were visualized by confocal microscopy.
Antisera—Polyclonal antisera were generated in rabbits against a
conserved peptide (RSHRRASSGDRLKD) conjugated via an added cys-
teine residue at the N-terminal region (Sigma Genosys). The third bleed
was affinity-purified.
Endothelial Cell Capillary Tube Formation Assays—HUVECs (8 
105 in 100-mm dishes) were infected with either pAdTrack-CMV-
p68RacGAP or pAdTrack-CMV (at a multiplicity of infection of 30) in
serum-free medium. Three hours after infection, the medium was sub-
stituted with standard endothelial cell growth medium (Clonetics) and
incubated for 48 h. HUVECs were then trypsinized, and 2.5  105 cells
were plated in 6-well plates precoated with Matrigel and incubated.
Twelve hours later, cells were fixed with blocking buffer as described
above and visualized by fluorescence microscopy with or without a
GFP filter.
Transfection, Luciferase Assays, and Immunohistochemistry—Vezf1
was co-transfected with human endothelin-1 promoter fragment
(pGL2–204/170) and increasing concentrations of p68RacGAP into
MECs using luciferase as our reporter gene as described previously
(13). Adult mouse tissues were prepared as described previously (17)
and incubated with purified polyclonal antibody generated against a
conserved peptide of p68RacGAP.
RESULTS
Cloning of a Novel RhoGAP-containing Protein by Interac-
tion with Vezf1 in a Yeast Two-hybrid Screen—The central
paradigm of transcriptional regulation relies on the molecular
interaction between a transcription factor and multiple regu-
latory proteins that unite to reconstitute an active transcrip-
tion factor unit that binds to a downstream promoter or en-
hancer for transcriptional activation or repression. Little is
known about regulatory proteins that interact with Vezf1 to
mediate its transcriptional or signaling mechanisms. We hy-
pothesized that such regulatory proteins will likely be ex-
pressed in a spatial and temporal relationship with Vezf1.
Therefore, we utilized the zinc finger domains of Vezf1 (Fig. 1A)
in a yeast two-hybrid system to screen 1  107 independent
clones of an embryonic day 10.5 mouse embryo cDNA library.
Of these, 11 potential positive clones survived selection. After
plasmid rescue and sequencing, one of the 11 was found to
contain a 1.8-kb fragment with a poly(A) tail that represents
the 3 cDNA sequence of a novel gene in-frame with the GAL4
activation domain. This 1.8-kb SalI-NotI fragment was ex-
tended by 5-rapid amplification of cDNA ends to obtain the
full-length cDNA sequence of 2,073 bp (Fig. 1B). The cDNA
contains a single open reading frame that initiates 276 base
pairs downstream of an in-frame stop codon and encodes a
protein of 571 amino acids with a predicted molecular mass of
68 kDa (GenBankTM accession number AY541447). In vitro
transcription and translation using this cDNA as a template
produced a specific protein product of the expected size, vali-
dating the predicted open reading frame. The primary amino
acid sequence contains a predicted RhoGAP domain at its N
terminus and a partial ezrin-radixin-moesin (ERM) domain
typical of proteins involved in membrane recruitment at its C
terminus. The RhoGAP domain, which is phylogenetically sim-
ilar to other RhoGAP-containing proteins (Fig. 1C), contains
the invariant arginine finger at position 70 that is character-
istic of RhoGAP proteins and that is functionally critical for
GTPase rate enhancement. For reasons explained subse-
quently, we have called this protein p68RacGAP.
We confirmed the specificity of our two-hybrid interaction
with two stringent assays. First, we measured activation of the
lacZ gene by activation domain fusion in yeast (Fig. 2A). -Ga-
lactosidase activity was only detected when the p68RacGAP
activation domain fusion was expressed in yeast containing the
zinc finger domain of Vezf1 fused with the GAL4 DNA binding
domain. It is notable that the strength of the p68RacGAP
interaction with its binding partner is greater than that of T
FIG. 2. Verification of in vivo interaction of p68RacGAP with
Vezf1. A, yeast transfectants containing the indicated plasmids were
grown under growth-resistant conditions (His, Ura). Growth and
-galactosidase activity were only detected in yeast transfected with
p68RacGAP and Vezf1. B, binding assay of recombinant Vezf1 and
p68RacGAP. Cell lysates from COS-7 cells transfected with vector or
Myc-p68RacGAP were incubated with recombinant GST or GST-
p68RacGAP. GST-Vezf1 binds avidly to Myc-p68RacGAP, but GST it-
self does not. C, interaction of p68RacGAP and Vezf1 in endothelial
cells. Cell lysates from non-transfected MECs were incubated with a
polyclonal antibody to p68RacGAP. Vezf1 specifically co-immunopre-
cipitated with p68RacGAP but was not pulled down with preimmune
serum. NS, nonspecific.
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antigen with p53, its well characterized interacting protein.
Second, we tested the binding efficiency of p68RacGAP, ex-
pressed in mammalian NIH/3T3 cells, with recombinant Vezf1,
expressed as a GST fusion protein in a GST binding assay. As
shown in Fig. 2B, p68RacGAP avidly binds GST-Vezf1 but not
GST alone. The result of this experiment confirms that
p68RacGAP is a binding partner for Vezf1 and strengthens the
validity of our two-hybrid screen. We tested the hypothesis that
the interaction between endogenous Vezf1 and p68RacGAP
occurs in vivo in endothelial cells by immunoprecipitating cell
lysates from MECs with polyclonal antibody to a conserved
peptide of p68RacGAP. As shown in Fig. 2C, Vezf1 is efficiently
co-immunoprecipitated with p68RacGAP in endothelial cells.
This experiment indicates that p68RacGAP is expressed in
endothelial cells and that it interacts with Vezf1, suggesting
that p68RacGAP might modify the transcriptional activity of
this nuclear protein.
Tissue Distribution of p68RacGAP—As a first step in the
characterization of p68RacGAP, we examined the expression of
p68RacGAP mRNA in adult mouse tissues and cell lines by
Northern blot analysis. Hybridization with the 1.8-kb C-termi-
nal fragment originally obtained from our yeast two-hybrid
screen (which lacks the RhoGAP domain) with polyadenylated
mouse RNA resulted in bands of different sizes between 2.0 and
3.0 kb, indicating the occurrence of tissue-specific mRNA proc-
essing (Fig. 3A). p68RacGAP mRNA was most abundant in two
highly vascular organs (kidney and lung) as well as in brain;
furthermore there was moderate expression of p68RacGAP in
the heart and relatively little or no expression in skeletal
muscle and liver (Fig. 3A). The robust expression of
p68RacGAP in highly vascular tissues suggested that
p68RacGAP might be differentially expressed in endothelial
cells and possibly endothelial cell-enriched tissues. Hybridiza-
tion to RNA from multiple cell lines showed that p68RacGAP
was highly expressed in endothelial cell lines: MECs, C166,
and rabbit endothelial vascular cells (Fig. 3B); however, we did
not detect similar expression in the non-endothelial cell lines
we examined, suggesting that p68RacGAP is predominately
expressed in endothelial cells and/or their precursors. Immu-
nohistochemical staining of large and medium sized arteries of
adult mice with purified polyclonal antibody raised against a
conserved peptide of p68RacGAP indicated that p68RacGAP is
predominantly expressed in endothelial cells of myocardial tis-
sues and epithelial cells of pulmonary tissues (Fig. 3C, a and b).
We also noted expression of p68RacGAP in choroid plexus,
Purkinje cells of the cerebellum, and in some myocardial cells
(data not shown). P68RacGAP peptide efficiently competed
with p68RacGAP antibody and prevented its binding to mouse
tissues (Fig. 3C, c and d) indicating that p68RacGAP efficiently
identifies tissues that express p68RacGAP.
FIG. 3. Tissue and cellular distribu-
tion of p68RacGAP. A, Northern analy-
sis with a p68RacGAP cDNA probe of
polyadenylated RNA from adult mouse
tissues. Filters were probed with -actin
to visualize RNA loading. p68RacGAP
RNA was highest in the lung, kidney, and
brain. B, Northern analysis with a
p68RacGAP cDNA probe of total RNA
from the indicated cell lines. p68RacGAP
RNA was only detected in the endothelial
cells tested but not in other cells. C, im-
munohistochemical analysis of adult
mouse tissues with a polyclonal antibody
(2.5 g/ml) to a conserved p68RacGAP
peptide alone or antibody plus peptide.
p68RacGAP is detected in endothelial
cells of intramyocardial vessels (a) and
bronchial epithelial cells (b). However,
the p68RacGAP peptide (25 g/ml) effi-
ciently competed and blocked binding of
the antibody to the tissues (c and d).
REVC, rabbit endothelial vascular cells.
p68RacGAP Is a Novel GTPase-activating Protein 17967
p68RacGAP Preferentially Binds and Hydrolyzes Rac1—
Since p68RacGAP has a putative RhoGAP domain, we chose to
characterize its RhoGAP activity. As a first step, we investi-
gated the effect of p68RhoGAP on binding to RhoA, Rac1, and
Cdc42, the three best characterized members of the family.
These binding assays are predicated on the observation that
RhoGAPs binds preferentially to the GTP-bound GTPase. We
incubated recombinant non-hydrolyzable (constitutively GTP-
bound) GST-RhoA, -Rac1, or -Cdc42 with p68RacGAP- or
p50RhoGAP-expressing cell lysates. p68RacGAP preferentially
bound Rac1 but not RhoA or Cdc42 (Fig. 4A). As a positive
control in these studies, p50RhoGAP bound RhoA, Rac1, and
Cdc42 indiscriminately as expected. These results clearly dem-
onstrate that p68RacGAP specifically binds Rac1, suggesting
that p68RacGAP may modulate Rac-specific cellular activity.
To test the GAP activity of p68RacGAP and its possible speci-
ficity for Rac1 in vivo, we incubated cell lysates from COS-7
cells transiently transfected with wild type Rho proteins
(RhoA-WT, Rac1-WT, or Cdc42-WT) or their genetically engi-
neered GTPase-deficient and GAP-insensitive derivatives
(RhoAQ63L, Rac1Q61L or Cdc42Q61L respectively) with
p68RacGAP, p50RhoGAP, or vector. As shown in Fig. 4B, in the
presence of p68RacGAP, a significantly smaller amount of
GTP-Rac1-WT could be pulled down with GST-PBD (a target
FIG. 4. GTPase binding and in vivo
RacGAP activity of p68RacGAP. A, ly-
sates from COS-7 cells transfected with
Myc-p68RacGAP or Myc-p50RhoGAP
were incubated with the indicated GST
fusion proteins. After precipitation with
glutathione-Sepharose conjugates, immu-
noblotting was performed with anti-Myc
antibodies to detect protein-protein inter-
actions. p68RacGAP bound GTP-loaded
Rac1 (GST-Rac1Q61L) in this assay but
not Cdc42 or RhoA. B–E, COS-7 cells
transfected with the indicated plasmids
were incubated with GST-PBD, which
binds GTP-loaded Rac1 or Cdc42 (B, C,
and E), or GST-RBD, which binds GTP-
loaded Rho (D). p68RacGAP could hydro-
lyze Rac1 efficiently (B) but not Cdc42 (C),
RhoA (D), or the non-hydrolyzable Rac1,
Cdc42, or RhoA (B–D). p68RacGAP, lack-
ing an arginine finger (p68RacGAP-
R70A), lacks the ability to hydrolyze Rac1
when compared with wild type protein
(E). WCL, whole cell lysate.
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binding protein that can only bind to the GTP-bound forms of Rac
and Cdc42 but not RhoA) suggesting that p68RacGAP hydro-
lyzed GTP-Rac1 to GDP-Rac1 so that it cannot bind to GST-PBD.
As expected, p68RacGAP did not have any effect on the GAP-
insensitive form of Rac1. Interestingly p68RacGAP hydrolyzed
GTP-bound Rac1 more efficiently than the well characterized
p50RhoGAP that was used as a positive control. Furthermore
p68RacGAP did not hydrolyze either wild type GTP-bound Cdc42
or RhoA, although these proteins were respectively hydrolyzed
by their cognate GAPs p50RhoGAP and p190RhoGAP (Fig. 4, C
and D). These results indicate that p68RacGAP has a func-
tional RhoGAP domain with a potent in vivo RhoGAP activity
that specifically targets Rac1 but not Cdc42 or RhoA.
The Arginine Finger Is Required for p68RacGAP in Vivo
RacGAP Activity—It has been reported that an arginine finger
is a critical residue that is required for the GTPase rate en-
hancement of RhoGAP-containing proteins. The arginine fin-
ger is an amino acid residue that points to the active site of its
corresponding small GTP-binding protein and, through its jux-
taposition to the active site, neutralizes the developing charges
in the transition state of the reaction and stabilizes the critical
glutamine residue, thus enhancing the intrinsic GTPase activ-
ity. The arginine finger is invariant within a subfamily of GAPs
and is conserved in p68RacGAP, and when studied in other
GAPs, mutations in this evolutionarily conserved residue dras-
tically impair GAP activity without changing binding affinity
(18). We tested the significance of the arginine finger of
p68RacGAP by replacing arginine 70 with alanine (p68RacGAP-
R70A). Consistent with the activity of other known GAPs, this
single amino acid substitution abolished the in vivo GAP ac-
tivity of p68RacGAP (Fig. 4E). Mutagenesis of the p68RacGAP
arginine finger and the subsequent loss of Rac1 GAP activity
provides further evidence that p68GRacGAP is a bona fide
GTPase-activating protein for Rac1 and that its GAP function
is similar or identical to that of other RhoGAPs.
p68RacGAP Inhibits Rac1-dependent Lamellipodia Forma-
tion—One of the cardinal characteristics of Rho GTPases is
their role in actin cytoskeletal reorganization. The activation of
Rho, Rac, and Cdc42 by extracellular signals has been well
characterized in a wide variety of cell types including 3T3
fibroblasts (2). In these cells, bradykinin activates Cdc42 to
produce filopodia, platelet-derived growth factor (PDGF) acti-
vates Rac to elicit lamellipodia extensions and membrane ruf-
fling, and lysophosphatidic acid (LPA) activates Rho leading to
formation of actin stress fibers and formation of associated
focal adhesion (19). Thus, Rho, Rac, and Cdc42 regulate three
distinct signal transduction pathways linking plasma mem-
brane receptors to the assembly of distinct filamentous actin
structures. To test the effect of p68RacGAP on actin cytoskel-
etal reorganization, we infected NIH/3T3 cells with an adeno-
virus that bicistronically expresses p68RacGAP and GFP that
was then compared with an adenovirus expressing GFP alone.
After 16 h of serum withdrawal, cells were challenged for 10
min with 100 ng/ml bradykinin, 10 ng/ml PDGF, or 20 ng/ml
LPA. Cells expressing p68RacGAP became insensitive to PDGF
under conditions that readily enhance Rac1-induced lamellipo-
dia formation (arrows) in the GFP expressing cells (Fig. 5);
however, p68RacGAP did not have any effect on bradykinin-
induced filopodia extension or LPA-induced stress fiber forma-
tion. This result indicates that p68RacGAP specifically inhibits
Rac1-mediated cytoskeletal reorganization, further buttressing
our observation that p68RacGAP has a Rac1-specific binding
and GTPase-activating function.
p68RacGAP Co-localizes with Vezf1 and Inhibits Vezf1-
dependent Transcriptional Activation of the Endothelin-1 Pro-
moter—As stated above, p68RacGAP was cloned based on its
interaction with the endothelial cell-specific transcription fac-
tor Vezf1. We have also shown that p68RacGAP avidly binds
and interacts with Vezf1 in non-endothelial and endothelial
cells (Fig. 2, B and C). Therefore, we hypothesized that a
juxtaposition of both regulatory proteins, possibly by co-local-
ization, might create an avenue for this in vivo interaction.
This would provide a potential point of interaction between Rac
signaling and transcriptional events within the endothelium.
We tested this hypothesis by co-transfecting NIH/3T3 cells
with GFP-Vezf1 and p68RacGAP or a closely related protein,
p50RhoGAP (also known as RhoGAP1, see Fig. 1C) and observ-
ing their localization by confocal microscopy. Consistent with
our previous observations (13), Vezf1 is localized to the nucleus
(Fig. 6, B); in contrast, p68RacGAP and p50RhoGAP are
largely localized to the cytoplasm (Fig. 6, A and B, arrow).
However, when the expression of Vezf1 and p68RacGAP was
examined simultaneously, we found that a significant fraction
of p68RacGAP co-localized with Vezf1 in the nucleus and that
FIG. 5. Effect of p68RacGAP on actin cytoskeletal changes in-
duced by PDGF, LPA, and bradykinin in NIH/3T3 cells. NIH/3T3
cells were infected with adenovirus that bicistronically expresses GFP
and p68RacGAP or GFP alone. After 12 h of serum withdrawal, cells
were incubated with 10 ng/ml PDGF, 20 ng/ml LPA, or 100 ng/ml
bradykinin as indicated for 10 min prior to fixation. Filamentous actin
was visualized with Texas Red-conjugated phalloidin staining (left pan-
els). GFP was visualized by fluorescence microscopy (right panels).
Arrows indicate lamellipodia.
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a fraction of Vezf1 was localized in the cytoplasm (Fig. 6A).
Co-expression of p50RhoGAP and Vezf1 did not affect the in-
trinsic localization of either protein (Fig. 6B). The results of
this experiment indicate that the interaction of p68RacGAP
and Vezf1 may affect protein trafficking, suggesting a potential
mechanism for interaction of the two regulatory proteins
p68RacGAP and Vezf1, and that this interaction may modulate
Rac signaling and/or the transcriptional activity of Vezf1.
Since we have previously shown that Vezf1 potently transac-
tivates the endothelin-1 promoter (13), we utilized this transcrip-
tional activity as a model to test the effect of p68RacGAP on
Vezf1-dependent gene regulation. Vezf1 was co-transfected with
increasing concentrations of p68RacGAP along with pGL2–204/
170 (an endothelin-1 promoter-reporter vector) into MECs, and
the transcriptional activity of the endothelin-1 promoter was
determined by measuring normalized luciferase activity. As
shown in Fig. 6C, p68RacGAP potently and dose-dependently
inhibited the Vezf1-dependent transactivation of the endothe-
lin-1 promoter activity. However, p68RacGAP did not have any
effect on the basal activity of pGL2-Basic, pGL2-Promoter, or
pGL2-Flk-1 (Fig. 6D), indicating that p68RacGAP is not a non-
specific inhibitor of transcription. This experiment supports our
FIG. 6. Subcellular and functional interactions of p68RacGAP and Vezf1. A and B, NIH/3T3 cells were transfected with GFP-Vezf1 and
Myc-p68RacGAP (A) or Myc-p50RhoGAP (B). Cells were visualized by confocal microscopy. GFP-Vezf1 localizes to the nucleus, while p50RhoGAP
and p68RacGAP localize predominantly to the cytoplasm (arrow in A and B). However, co-expression of both Vezf1 and p68RacGAP proteins results
in co-localization of p68RacGAP and Vezf1 to the nucleus (indicated by yellow color in merged image) and cytoplasmic relocalization of a portion
of Vezf1 (A); however, expression of both Vezf1 and p50RhoGAP did not result in co-localization or translocation of either protein outside of their
normal location (B). Morphology of cells is indicated by differential interference contrast (DIC). C, to test whether p68RacGAP affects Vezf1-de-
pendent transactivation of the endothelin-1 promoter activity, MECs were transfected with the indicated amounts of Vezf1 and Myc-p68RacGAP
and 1.0 g of pGL2–204/170 (an endothelin-1 promoter-luciferase reporter vector). The vector pCMV-Gal was used to correct for differences in
transfection efficiency. Increasing concentrations p68RacGAP resulted in a dose-dependent transcriptional inhibition of endothelin-1 activity. D,
to test whether p68RacGAP is a nonspecific transcriptional inhibitor, MECs were transfected with pGL2-Basic, pGL2-Promoter, and pGL2-Flk1
with and without p68RacGAP. As shown, p68RacGAP did not affect their basal transcriptional activity.
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previous observation that p68RacGAP interacts with Vezf1 (Fig.
2, A, B, and C) and indicates that p68RacGAP specifically mod-
ulates Vezf1-dependent transcriptional activity.
p68RacGAP Modulates Endothelial Cell Capillary Tube For-
mation—One of the first steps during vascular development is
the differentiation of endothelial cells from pluripotent stem
cells, the formation of primitive tubes, and the recruitment of
surrounding mesenchymal cells that eventually differentiate
into vascular smooth muscle cells. The migration of these cells
in the correct spatial and temporal organization ultimately
leads to the formation of mature vascular tissues and organs.
This complex assembly and patterning of the capillary plexus is
regulated by a wide array of developmental cues that lead to
morphological and Rho-mediated cytoskeletal change involving
disassembly and reassembly of actin structures that provide
the structural framework that ultimately defines cell shape
and polarity. It has been shown previously that Rac1 regulates
endothelial capillary tube assembly (8). Based on our expres-
sion analysis and functional characterization, we sought to
determine whether p68RacGAP might modulate Rac1-depend-
ent endothelial cell assembly into capillary tubes. We infected
HUVECs with adenovirus co-expressing p68RacGAP with GFP
or GFP alone. Forty-eight hours later, cells were trypsinized
and plated on 6-well plates precoated with Matrigel (Fig. 7).
GFP-infected cells formed a network of capillary tube-like
structures that recapitulates branching morphogenesis of an-
giogenesis (upper panels); however, the p68RacGAP-infected
HUVECs thrived but were resistant to formation of capillary
tube-like structures under the same conditions that stimulated
endothelial cell differentiation in GFP-infected cells (lower
panels). This experiment suggests that p68RacGAP inhibits
Rac1 and prevents the formation of protrusive lamellipodia
formation necessary for the coordinated migration of endothe-
lial cells in the presence of the appropriate extracellular signal.
DISCUSSION
We have taken a molecular and cellular approach to under-
stand the function of Vezf1, a developmentally regulated endo-
thelial cell-specific transcription factor, as part of a larger effort
to understand the molecular steps that determine pattern-
forming events that result in creation of blood vessels. In ad-
dition to defining cis-acting elements and downstream target
genes (13), we have searched for interaction networks that may
explain how Vezf1 contributes to angiogenesis. In the course of
these studies, we have discovered p68RacGAP, a Rac-specific
GTPase that interacts with Vezf1 in vitro and in vivo and that
also inhibits endothelial cell migration and tube formation.
The RhoGAP proteins, like Rho GTPases, are found in eu-
karyotes ranging from yeast to humans, suggesting an evolu-
tionarily conserved role in eukaryotic cell regulation. Since the
identification of the Breakpoint cluster region protein, BCR, as
a RhoGAP in 1991 (20), the number of RhoGAPs (about 80)
outnumbers the 25 Rho GTPase substrates (3). This suggests
that multiple GAP proteins have a specific role in regulating
distinct functions of each GTPase. The importance of the reg-
ulatory function of GAP proteins is underscored by the loss of
GAP function due to mutation of the tumor suppressor neuro-
fibromin 1, a GAP that is a negative regulator of the Ras signal
transduction pathway. Patients with mutations in neurofibro-
min 1 are at increased risk of developing nervous system neo-
plasms seen in type 1 neurofibromatosis (21). In addition, mu-
tations in oligophrenin-1, a RhoGAP protein that affects cell
migration and morphogenesis, leads to X-linked mental retar-
dation (22). Finally recent studies of p190 RhoGAP showing
that RhoGAPs are required for axon outgrowth, guidance, and
fasciculation further underscore the necessary role for these
proteins in cellular physiology (23). By analogy, it is likely that
p68RacGAP regulates a subset of endothelial events regulated
by Rac activity or that it couples Rac activation to other events
within the vasculature. Given our observation that increasing
p68RacGAP levels inhibit endothelial cell tube formation in
cultured cells (Fig. 7), endothelial cell migration and angiogen-
esis are among the promising key cellular and physiologic
processes regulated by this new GAP.
Although the present studies focused on cell migration in the
context of angiogenesis as a function of Rac within the endo-
thelium, it is important to recognize that Rac has multiple roles
within the endothelium, any of which may be specifically mod-
ulated by RacGAPs such as p68RacGAP. Rac1 and Rac2 are
necessary components of the vascular NADPH oxidase that
produces an oxidative burst in response to mitogenic stimuli
FIG. 7. p68RacGAP modulates endo-
thelial cells capillary tube formation.
HUVECs were infected with an adenovi-
rus that bicistronically expresses GFP
and p68RacGAP (lower panels) or GFP
alone (upper panels). Forty-eight hours
later, cells were plated in 6-well plates
precoated with Matrigel and allowed to
form capillary tubes for 12 h. Cells were
fixed and examined by fluorescence (left
panels) and light (right panels) micros-
copy. Cells infected with p68RacGAP are
resistant to differentiation and formation
of capillary tubes compared with the
GFP-only infected cells.
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and that is required for signaling downstream of thrombin and
other vascular growth factors (24). Integrin-specific cell cycle
progression in endothelial cells is controlled by activation of
Rac (25), and expression of endothelial chemoattractant pro-
teins is also Rac-dependent (26). It is likely that individual
RacGAPs function in distinct Rac-dependent cellular events in
the endothelial compartment. Remarkably such a model has
not yet been tested extensively for any RacGAP family mem-
ber, and almost nothing is known about the role of specific
RacGAPs in phenotypic modulation of endothelial cells. Anal-
ysis of p68RacGAP may therefore provide an important method
to understand how Rac-dependent signaling contributes to di-
verse but tightly regulated events within the endothelium.
Our studies indicate that p68RacGAP is both a GAP for Rac
family members and a Vezf1 interaction partner; these dispar-
ate activities allow us to build a model that can form the basis
for additional studies to refine the function of this new protein.
It is tempting to speculate that p68RacGAP provides a tool for
integrating the regulation of several levels of signaling events
within the endothelium. In particular, our data suggest that
p68RacGAP can dually inhibit Rac signaling and Vezf1-de-
pendent transcriptional events. Although the function of Vezf1
within the endothelium is incompletely understood, studies to
date suggest a role for this transcription factor in regulation of
developmental angiogenesis and perhaps vasomotor tone in
adulthood (11, 13). Thus, p68RacGAP may allow endothelial
cells to arrest angiogenic responses at multiple key steps and
also to coordinate signaling and transcription during pheno-
typic modulation of blood vessels. Interactions between Rho
signaling and transcription during vascular smooth muscle cell
differentiation have recently been demonstrated in studies ex-
amining the influence of Rho-dependent cytoskeletal rear-
rangements on serum response factor activation (27), providing
a precedent for such cross-talk in vascular cells. However,
despite the fact that proteins with GAP activity are frequently
dependent on protein-protein interactions to regulate their ac-
tivity, interactions with transcription factors have not previ-
ously been recognized in any biological context (6). To our
knowledge, the association of Vezf1 and p68RacGAP repre-
sents the first example.
One puzzle in such a model is where and when p68RacGAP
interacts with a binding partner such as Vezf1. Our confocal
microscopy data indicate that p68RacGAP is predominantly
distributed within the cytoplasm (Fig. 6A), which would be
consistent with its role in regulating Rac activity. We have
previously shown that Vezf1 is predominantly nuclear localized
(13); however, our current data show that interaction of both
regulatory proteins may lead to trafficking of both proteins
outside of their usual cellular compartment. It is possible that
p68RacGAP and/or Vezf1 undergo nucleocytoplasmic shuttling
under appropriate conditions to maximize the possibility of
interaction. However, we also observed a highly reproducible
overlap in expression of Vezf1 and p68RacGAP in the nuclear
space even in the absence of specific stimulation (Fig. 6A). This
expression pattern is reminiscent of the interaction between
Vezf1 and another protein in the Rho signaling family, RhoB,
that was recently demonstrated by Prendergrast and col-
leagues (28). RhoB interacts with Vezf1 only in the perinuclear
space, and RhoB inhibits Vezf1-dependent transcriptional reg-
ulation. Taken together with the experiments presented here,
these data suggest that Vezf1 is particularly receptive to reg-
ulation that occurs in and adjacent to the nuclear membrane;
perhaps the nuclear and perinuclear space represents a previ-
ously unsuspected locus for enriched activity of Rho family
members particularly when they are required to modulate
transcriptional activity. Although we did not test the reverse
possibility in our present studies, it is equally plausible that
reciprocal interactions also exist and that activation of Vezf1
also affects Rac activity. These studies will be possible and
potentially informative when more is known about how Vezf1 is
regulated at the cellular level.
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